Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-92505 in Advanced Solid Tumors
NCT07896460Phase 1Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2026
- Primary completion
- Aug 2028
01
Overview
Phase 1, open-label trial of BG-92505 in solid tumor (3 arms), sponsored by BeOne Medicines. Primary endpoints: Dose-Limiting Toxicities at 1 month and Adverse Events at 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BG-92505
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07896460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896460.